<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021749</url>
  </required_header>
  <id_info>
    <org_study_id>GL208</org_study_id>
    <secondary_id>G3139</secondary_id>
    <secondary_id>Bcl-2 Antisense</secondary_id>
    <nct_id>NCT00021749</nct_id>
    <nct_alias>NCT00021190</nct_alias>
  </id_info>
  <brief_title>Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Phase I-II Multicenter Study of Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Advanced Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genta Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genta Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-randomized study will test the safety and effectiveness of Genasense in patients
      with CLL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a two-part phase I-II study. Part 1 will determine the MTD of Genasense in
      patients with CLL. This dose will then be tested in a non-randomized, multi-center, Phase II
      sequential clinical trial of Genasense used alone for treatment of patients with advanced
      CLL.

      Pharmacokinetics of Genasense and kinetics of Bcl-2 down regulation and re-expression in CLL
      cells will be followed in selected patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2001</start_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>CLL</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oblimerson sodium, G3139</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Any age

          -  Must have received at least one chemotherapy regimen that included fludarabine

          -  Measurable disease

          -  At least 3 weeks since biological therapy or radiation therapy for chronic lymphocytic
             leukemia

          -  No previous stem cell transplantation

          -  At least 3 weeks since surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Cancer Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol. 2005 Oct 20;23(30):7697-702. Epub 2005 Sep 26.</citation>
    <PMID>16186597</PMID>
  </results_reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2001</study_first_submitted>
  <study_first_submitted_qc>August 4, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2001</study_first_posted>
  <last_update_submitted>November 10, 2009</last_update_submitted>
  <last_update_submitted_qc>November 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2009</last_update_posted>
  <keyword>CLL</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Chronic</keyword>
  <keyword>Cancer</keyword>
  <keyword>Adult</keyword>
  <keyword>Lymphocytic</keyword>
  <keyword>Genasense</keyword>
  <keyword>G3139</keyword>
  <keyword>Genta</keyword>
  <keyword>Bcl-2</keyword>
  <keyword>Antisense</keyword>
  <keyword>Oligonucleotide</keyword>
  <keyword>oblimerson</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

